

Chondrosarcoma: Why Grade and Location Change Treatment

Three details to clarify in your report: the tumour's exact type, its grade and where it is growing.

Dr. Vishnu Baburaj

Published 29 October 2026 · Updated 29 October 2026 · Clinically reviewed 29 October 2026

<https://drvishnubaburaj.com/blog/oncology/chondrosarcoma-grade-location-treatment/>



Chondrosarcoma describes a family of tumours that produce cartilage. Their behaviour varies with grade and subtype, and treatment also depends on where the tumour is growing. The name alone does not tell you which operation or other treatment is appropriate.^[1]

It can be confusing to hear that one cartilage tumour is monitored while another needs major surgery. The comparison becomes more useful once you know the exact diagnosis, grade and site. Keep those three details together when reading your report; they are what the rest of this article will explain.^[1]

What does the grade mean?

Conventional chondrosarcoma is graded from 1 to 3 using microscopic features, including the appearance and activity of its cells. Higher grades generally indicate more aggressive behaviour. Rare subtypes, including mesenchymal, dedifferentiated and clear-cell chondrosarcoma, need their own assessment.^[1]

Grading is not always straightforward. A needle biopsy provides a limited sample, and different parts of a cartilage tumour can look different. The grade must therefore be interpreted with the imaging and clinical findings by a team experienced in bone tumours.^[2]

In the pelvis, a biopsy labelled “low grade” particularly needs review alongside the scans. A small sample may not represent the whole tumour.^[2]

More about the evidence

One retrospective diagnostic study found less agreement between biopsy and final surgical grading in pelvic tumours than in long-bone tumours. Its selected cohort cannot predict whether your own biopsy is accurate.^[2]

The biopsy and imaging need to make sense together. The specialist review should explain any uncertainty, how it affects the recommended treatment and what further information would help.

Dr. Vishnu's perspective

Let us first establish what the report confirms and what still needs specialist review. I also want to know which part is worrying you most. Is it the diagnosis, the possibility of surgery or something you have read? Before we compare treatment options, we should make room for that concern and be clear about any unanswered questions in your own report.

Why does location change the name and the plan?

The term **atypical cartilaginous tumour (ACT)** is used for appropriate low-grade tumours in the long and short tubular bones of the limbs. Similar-looking low-grade tumours in axial sites, including the pelvis, retain the name chondrosarcoma. ACT is classified as intermediate and locally aggressive; it is not simply another word for a harmless cartilage finding.^[1]

When can monitoring be considered?

Current UK bone sarcoma guidance allows initial observation of extremity ACTs. Symptoms or progression may lead to curettage, removal from within the bone, or excision.^[5]

Observation can be appropriate for selected long-bone cartilage lesions with reassuring imaging and no important tumour-related symptoms. This does not extend to every cartilage tumour, particularly those in the pelvis or with aggressive features.^[3]

More about the evidence

A retrospective MRI surveillance study examined selected enchondromas and ACTs in long bones without aggressive imaging features. Most remained stable or regressed during follow-up, but most lesions had no tissue diagnosis.^[3]

Monitoring includes a plan to reassess symptoms and imaging. New or increasing pain, growth or concerning scan changes should prompt review. Pain can also have another cause, so the assessment needs to establish whether it relates to the tumour.^[3]

A monitoring plan should leave you clear about the next review and how to report a change between appointments. It should include the contact route and the reason for observation, so that waiting for a scan does not feel like having no plan.

What changes when surgery is needed?

Higher-grade chondrosarcomas and those in the pelvis or axial skeleton generally need excision with wide margins. A low-grade peripheral chondrosarcoma arising from an osteochondroma also needs a different surgical approach from a central limb ACT.^[4]

For the surgical discussion, a drawing of the area to be removed can be more useful than the operation name alone. Bring up your actual priorities: walking outdoors, stairs, sitting comfortably or the demands of your work. These are questions about the proposed operation, not promises that every activity will return.

Why might chemotherapy or radiotherapy be discussed?

Surgery is central to treatment of localised conventional chondrosarcoma. Standard chemotherapy has a limited role in this subtype.^[1]

Mesenchymal and dedifferentiated chondrosarcoma need a separate chemotherapy discussion. Guidelines allow chemotherapy in selected cases, but the evidence and expected benefit differ between these subtypes. A recommendation for one should not be assumed to apply to the other.^[4]

Radiotherapy can be considered for an unresectable tumour, after incomplete surgery or for symptom relief. Certain sites, including the skull base, have specific radiotherapy recommendations. Suitability requires specialist planning; it is not a routine substitute for an achievable operation in every case.^[4]

Questions for the treatment discussion

- What is the exact subtype, grade and anatomical site?
- Do the biopsy and scans agree?

- Why is monitoring, curettage or wider excision being recommended?
- If another treatment is proposed, what is its purpose and what evidence supports it?
- What are the expected effects on movement, daily activities and further follow-up?

A written plan should distinguish agreed treatment from decisions still waiting for results. That gives later conversations a clearer starting point than comparing treatment names alone.

Frequently Asked Questions

Is an atypical cartilaginous tumour the same as every chondrosarcoma?

No. ACT describes an intermediate, locally aggressive cartilage tumour in appropriate limb bones. Other sites, higher grades and different subtypes can require different treatment. [\[1\]](#)

Can the grade change after the tumour is removed?

Yes. A needle biopsy samples part of the lesion, while the surgical specimen allows wider examination. A higher-grade area may be identified, particularly in a heterogeneous tumour. [\[2\]](#)

Why might an ACT be monitored instead of removed?

Selected lesions in long limb bones without aggressive imaging features or significant tumour-related symptoms may be suitable for surveillance. That evidence should not be applied to pelvic or high-grade tumours. [\[3\]](#)

Does chondrosarcoma never need chemotherapy or radiotherapy?

These treatments have roles in selected settings. Chemotherapy decisions differ by subtype; radiotherapy may be considered when removal is not possible, after incomplete surgery or to relieve symptoms. [\[4\]](#)

Your consultation

Discuss chondrosarcoma grade and treatment choices

To discuss your chondrosarcoma report and proposed treatment, you can book a consultation with Dr. Vishnu Baburaj at Aster MIMS Kannur.

[Book a consultation](#)

[Plan your visit](#)

The evidence behind this article

1. Gazendam A, Popovic S, Parasu N, Ghert M. *Chondrosarcoma: A Clinical Review*. Journal of Clinical Medicine. 2023;12(7):2506. [Full review](#). doi:10.3390/jcm12072506.

2. Roitman PD, Farfalli GL, Ayerza MA, Múscolo DL, Milano FE, Aponte-Tinao LA. *Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones?* Clinical Orthopaedics and Related Research. 2017;475(3):808-814. [Full diagnostic study](#).
 3. Deckers C, de Rooy JWJ, Flucke U, Schreuder HWB, Dierselhuis EF, van der Geest ICM. *Midterm MRI Follow-Up of Untreated Enchondroma and Atypical Cartilaginous Tumors in the Long Bones*. Cancers. 2021;13(16):4093. [Full observational study](#). doi:10.3390/cancers13164093.
 4. Strauss SJ, Frezza AM, Abecassis N, et al. *Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up*. Annals of Oncology. 2021;32(12):1520-1536. [Full guideline](#). doi:10.1016/j.annonc.2021.08.1995.
 5. Gerrand C, Amary F, Anwar H, et al. *UK guidelines for the management of bone sarcomas*. British Journal of Cancer. 2025;132:32-48. Published online 2024. [Guideline](#). doi:10.1038/s41416-024-02868-4.
-

Medically reviewed by Dr. Vishnu Baburaj, MS Ortho (PGI Chandigarh), MRCS (UK) · Last reviewed Oct 29, 2026

This article is for educational purposes and does not replace a medical consultation. For personalised advice, [book an appointment](#) at Aster MIMS Kannur.